Press releases

29 June, 2022

Regulatory

Abliva finishes SEK200M financing round with publication of rights issue outcome

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 1 June 2022 (th ...

20 June, 2022

Spots left: Abliva’s Fireside Chat in Lund and Stockholm

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and inves ...

14 June, 2022

Meet Abliva live: Fireside Chat in Lund and Stockholm

8 June, 2022

Regulatory

Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the new issues announced on 31 May, 2022, and the conversion of the Company's convertib ...

1 June, 2022

Regulatory

Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors

The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) has approved a directed issue of approximately SEK 150 million to several life science specialist and instituti ...

31 May, 2022

Regulatory

Abliva AB Interim Report January – March 2022

First quarter summary

31 May, 202222 February, 2024

Regulatory

Abliva targets SEK 200 million raise to fund the KL1333 Phase 2/3 study to interim analysis

Abliva AB (Nasdaq Stockholm: ABLI) today announced that it intends to raise a financing round of SEK 200 million to provide the company with the capital necessary to run the Phase 2/3 study with KL133 ...

20 May, 2022

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2022 held its Annual General Meeting (“AGM”). A summary of the resolutions follows.

19 May, 2022

Regulatory

Abliva to issue the Q1 Interim Report by May 31st

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that The Board of Directo ...

29 April, 2022

Regulatory

Abliva AB publishes 2021 Annual report

19 April, 2022

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 1 p.m. on Friday, 20 May 2022 at Medicon Village, Scheeletorget ...

22 February, 2022

Regulatory

Abliva AB Year-End Report January – December 2021

"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO